SLRX

Salarius Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website alariuspharma.com
Employees(FY) 12
ISIN US79400X4043

Performance

-3.45%

-30.35%

-26.32%

-64.61%

-73.08%

YTD

-74.22%

Profile

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

Advanced Technical Analysis

Technical Analysis of SLRX 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 46 suggesting a neutral stance, and a Technical Score of 28 reinforcing the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to be negat...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SLRX

Stock Rank

Recent News & Updates

2024-11-14 06:25
Salarius: Q3 Earnings Snapshot(Yahoo Finance)
2024-08-09 05:21
Salarius: Q2 Earnings Snapshot(Yahoo Finance)
2024-07-10 19:29
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday(Investorplace)
2024-06-16 20:00
Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting(Globenewswire)
2024-06-11 20:00
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split(Globenewswire)
2024-05-13 10:53
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024(Investorplace)
2024-05-13 04:43
Salarius: Q1 Earnings Snapshot(Yahoo Finance)
2024-03-22 09:52
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023(Investorplace)
2024-03-22 04:34
Salarius: Q4 Earnings Snapshot(Yahoo Finance)
2024-03-22 04:05
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update(Globenewswire)
2024-02-21 19:00
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses(Globenewswire)
2024-01-15 19:00
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders(Globenewswire)
2024-01-02 19:30
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment(Globenewswire)
2023-11-09 16:03
Salarius: Q3 Earnings Snapshot(Yahoo Finance)
2023-11-06 19:30
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program(Globenewswire)
2023-08-10 05:10
Salarius: Q2 Earnings Snapshot(Yahoo Finance)
2023-08-10 04:05
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update(Yahoo Finance)
2023-08-08 19:39
SLRX Pursuing Strategic Alternatives(Yahoo Finance)
2023-08-08 04:05
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources(Yahoo Finance)
2023-07-10 21:00
SLRX Continues Cancer Fight with Phase I Trial Approval(Yahoo Finance)
2023-07-10 20:30
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients(Yahoo Finance)
2023-06-11 20:00
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress(Yahoo Finance)
2023-05-16 04:05
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules(Yahoo Finance)
2023-05-11 20:00
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules(Yahoo Finance)
2023-05-10 20:20
Salarius: Q1 Earnings Snapshot(Yahoo Finance)
2023-05-10 20:00
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update(Yahoo Finance)
2023-05-08 20:00
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma(Yahoo Finance)
2023-05-08 19:34
SLRX: Fighting Cancer Through Two Paths(Yahoo Finance)
2023-04-30 20:30
Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164(Yahoo Finance)
2023-04-19 20:30
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.